Skip to main
  1. Stocks
  2. Zentalis Pharmaceuticals
  3. Forecast
ZNTL

Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

Zentalis Pharmaceuticals (ZNTL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zentalis Pharmaceuticals is viewed favorably because interim DENALI data suggest azenosertib can generate meaningful, biomarker-enriched benefit in Cyclin E1-positive platinum-resistant ovarian cancer, where median overall survival reached about 15.8 to 15.9 months versus 7.5 months in Cyclin E1-negative patients, alongside an updated ORR of 37.2%. The investment case is strengthened by improved tolerability signals, including roughly a 50% reduction in discontinuations and no new safety signals, which supports the 400 mg QD 5:2 dose and the broader non-chemotherapy strategy. Financially, Zentalis ended Q3 with $228.9M in cash, cash equivalents and marketable securities, and management believes that is sufficient to fund operations into 1H:28, providing runway through key upcoming readouts.

Bears say

Zentalis Pharmaceuticals is viewed negatively because its core value driver, azenosertib, still faces major clinical and regulatory risk, including the possibility that it may not prove efficacious or could generate safety signals serious enough to halt development. The company also depends heavily on a single lead asset for future growth, so any setback in the program would materially weaken its outlook and undermine confidence in its ability to advance from a clinical-stage biopharmaceutical company into a commercial one. Even if development succeeds, azenosertib may still struggle against current and future therapies, and the company may be unable to achieve sales estimates, leaving its long-term revenue potential uncertain.

Zentalis Pharmaceuticals (ZNTL) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zentalis Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Zentalis Pharmaceuticals (ZNTL) Analyst Forecast & Price Prediction

Get the latest Zentalis Pharmaceuticals (ZNTL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Zentalis Pharmaceuticals (ZNTL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zentalis Pharmaceuticals (ZNTL) Forecast

Analysts have given Zentalis Pharmaceuticals (ZNTL) a Buy based on their latest research and market trends.

According to 6 analysts, Zentalis Pharmaceuticals (ZNTL) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zentalis Pharmaceuticals (ZNTL)


Zentalis Pharmaceuticals (ZNTL) Analyst Forecast & Price Prediction

Get the latest Zentalis Pharmaceuticals (ZNTL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Zentalis Pharmaceuticals (ZNTL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ZNTL stock data and trends